SCHEMBL26260037

SCHEMBL26260037

COc1ccc2c(-c3cncnc3)c(OC)cc(-c3cncnc3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 9/20 0.53
▸ CYP11B2 P19099 9/20 0.53
▸ CYP17A1 P05093 6/20 0.53
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CYP3A4 P08684 5/20 0.39
▸ ERN1 O75460 1/20 0.38
▸ EGFR P00533 2/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ CYP1A2 P05177 3/20 0.37
▸ CYP2C9 P11712 3/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ CYP1A1 P04798 1/20 0.36
▸ CYP2E1 P05181 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26260061 0.82 KDM4E (0.57) CYP11B1CYP11B2CYP17A1KDM4EALDH1A1
SCHEMBL26259504 0.81 MAPK13 (0.46) CYP11B1CYP11B2KDM4EALDH1A1HPGD
SCHEMBL26260084 0.78 HIF1A (0.44) CYP11B1CYP11B2CYP17A1KDM4EALDH1A1
SCHEMBL26259484 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL8502557 0.77 CYP17A1 (0.55) CYP11B1CYP11B2CYP17A1KDM4EALDH1A1
SCHEMBL26260045 0.74 MAOB (0.46) CYP3A4ERN1CYP1A2CYP2C9CYP2D6
SCHEMBL26260002 0.73 F2 (0.44) KDM4EALDH1A1HSD17B10CYP3A4ERN1
SCHEMBL26260006 0.73 KMT2A (0.37) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL26260050 0.71 IMPDH2 (0.43) CYP11B1CYP11B2KDM4ECYP3A4CYP1A2
SCHEMBL26260063 0.70 CLK4 (0.44) KDM4EALDH1A1HPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND NUDC, CCNL2, SPIN3 CYP11B1 3382/4885CYP11B2 3279/4885CYP17A1 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback